Ticker
ABBV

Price
136.50
Stock movement up
+1.07 (0.79%)
Company name
AbbVie Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
240.81B
Ent value
353.12B
Price/Sales
4.15
Price/Book
13.93
Div yield
4.34%
Div growth
17.11%
Growth years
9
FCF payout
41.42%
Trailing P/E
20.35
Forward P/E
12.28
PEG
2.46
EPS growth
36.80%
1 year return
-6.84%
3 year return
13.30%
5 year return
6.58%
10 year return
12.08%
Last updated: 2023-06-07
AbbVie's share price has been slipping as its globally best-selling drug Humira has lost US patent protection. See why ABBV remains a magnet for investor money.
June 5, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
June 1, 2023

iO Charts is a Seeking Alpha partner

BUSINESS INSIGHT

Revenues per Product Category ($M)

Loading...
Company comments

AbbVie was created through a spinoff from Abbott Laboratories in 2013

Humira is the world’s #1 global pharmaceutical product by a large margin

AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications

Geographic Revenues ($M)

Loading...
Loading...
AD

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share5.92
Dividend yield4.34%
Payout frequencyQuarterly
Maximum yield7.32%
Average yield4.74%
Minimum yield3.22%
Discount to avg yield-9.37%
Upside potential-8.56%
Yield as % of max yield59.27%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield4.34%
Current yield distribution63.49%
Yield at 100% (Min)3.22%
Yield at 90%3.76%
Yield at 80%3.96%
Yield at 50% (Median)4.80%
Yield at 20%5.39%
Yield at 10%5.77%
Yield at 0% (Max)7.32%

Dividend per share

Loading...
Dividend per share data
Years of growth9 years
CCC statusDividend Challenger
Dividend per share5.92
Payout frequencyQuarterly
Ex-div date13 Apr 2023
EPS (TTM)6.66
EPS (1y forward)11.12
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
ABBVS&P500
DGR MR4.96%-15.45%
DGR TTM6.64%11.27%
DGR 3 years9.63%4.00%
DGR 5 years17.11%5.65%
DGR 10 years-7.37%
DGR 15 years-5.83%
Time since last change announced224 days
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM84.85%41.42%
Average--
Forward53.24%-
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
June 1, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
June 1, 2023

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E20.35
Price to OCF9.65
Price to FCF9.93
Price to EBITDA10.42
EV to EBITDA15.28

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.15
Price to Book13.93
EV to Sales6.08
Loading...
AD

FINANCIALS

Per share

Loading...
Per share data
Current share count1.76B
EPS (TTM)6.66
FCF per share (TTM)13.64

Income statement

Loading...
Income statement data
Revenue (TTM)58.05B
Gross profit (TTM)40.64B
Operating income (TTM)18.36B
Net income (TTM)11.84B
EPS (TTM)6.66
EPS (1y forward)11.12

Margins

Loading...
Margins data
Gross margin (TTM)70.00%
Operating margin (TTM)31.63%
Profit margin (TTM)20.39%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash9.20B
Net receivables11.25B
Total current assets28.46B
Goodwill32.16B
Intangible assets67.44B
Property, plant and equipment0.00
Total assets138.81B
Accounts payable25.40B
Short/Current long term debt63.27B
Total current liabilities29.54B
Total liabilities121.52B
Shareholder's equity17.29B
Net tangible assets-82.34B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)24.94B
Capital expenditures (TTM)695.00M
Free cash flow (TTM)24.25B
Dividends paid (TTM)10.04B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity68.47%
Return on Assets8.53%
Return on Invested Capital14.69%
Cash Return on Invested Capital30.10%
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
May 31, 2023

iO Charts is a Seeking Alpha partner

AbbVie reported Q1 results on April 27th, and the stock is down about 10% since. Check out if the drop makes ABBV stock a buy.
May 21, 2023

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open134.90
Daily high137.06
Daily low134.28
Daily Volume4.58M
All-time high174.96
1y analyst estimate163.87
Beta0.59
EPS (TTM)6.66
Dividend per share5.92
Ex-div date13 Apr 2023
Next earnings date27 Jul 2023

Downside potential

Loading...
Downside potential data
ABBVS&P500
Current price drop from All-time high-21.98%-10.71%
Highest price drop-48.88%-56.47%
Date of highest drop15 Aug 20199 Mar 2009
Avg drop from high-14.19%-11.53%
Avg time to new high18 days13 days
Max time to new high975 days1805 days
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
May 21, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
May 19, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ABBV (AbbVie Inc) company logo
Marketcap
240.81B
Marketcap category
Large-cap
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employees
50000
SEC filings
CEO
Richard Gonzalez
Country
USA
City
North Chicago
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
May 18, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
May 13, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
The incidence of irritable bowel syndrome is on the rise. New medications from AbbVie show signs of promise. Click here to read my analysis of ABBV stock.
May 10, 2023
AbbVie Inc. (ABBV Bank of America Securities Healthcare Conference May 9, 2023 11:00 AM ETCompany ParticipantsRob Michael - Vice Chairman & PresidentScott Reents - Executive Vice...
May 9, 2023
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
May 9, 2023
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
May 9, 2023
This article applies Peter Lynch's approach to evaluate AbbVie and Johnson & Johnson. Find out which is the better dividend stock.
May 9, 2023
AbbVie dropped almost 8% after its most recent earnings release. Read more to see why I rate ABBV stock a buy.
May 3, 2023
Both Gilead and AbbVie are strong picks for dividend investors. Each has had a mixed bag of positives and negatives. GILD has an edge over ABBV. Explore more here.
May 3, 2023
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
April 29, 2023
AbbVie's revenue amounted to $12,225 million in the first three months of 2023, 9.7% less than the previous year. Find out my recent analysis of ABBV stock.
April 28, 2023
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
April 27, 2023
iO Charts is a Seeking Alpha partnerNext page